The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
Hana KimSoomin AhnHongsik KimJung Yong HongJeeyun LeeSe Hoon ParkJoon Oh ParkYoung Suk ParkHo Yeong LimWon Ki KangKyoung-Mee KimSeung Tae KimPublished in: Journal of cancer research and clinical oncology (2021)
Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.